ArticleFrontiers in medicine2026
Microscopic polyangiitis with pulmonary involvement: Case Report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: ANCA-associated vasculitis is a rare autoimmune disorder characterized by necrotizing inflammation of small vessels, frequently affecting the kidneys and lungs, and may present as a potentially life-threatening pulmonary-renal syndrome during disease relapse. Case presentation: We present the case of a 66-year-old woman with a history of MPO-ANCA-associated vasculitis with prior renal and pulmonary involvement, who was admitted with acute respiratory failure and rapidly progressed to severe acute respiratory distress syndrome requiring invasive mechanical ventilation, along with acute kidney injury (KDIGO stage 3B) superimposed on chronic kidney disease. Laboratory findings revealed progressive anemia, elevated inflammatory markers, and markedly increased MPO-ANCA titers, compatible with vasculitis reactivation presenting as diffuse alveolar hemorrhage and pulmonary-renal syndrome. The patient was treated with pulse methylprednisolone, intravenous immunoglobulin, plasmapheresis, and rituximab, in addition to intensive supportive care. Her clinical course was complicated by a urinary tract infection caused by extended-spectrum beta-lactamase (ESBL)-producing Conclusion: This case highlights the diagnostic challenges and severity of MPO-ANCA vasculitis relapse, and underscores the importance of early recognition, prompt immunosuppressive therapy, and multidisciplinary management to improve outcomes, especially in healthcare settings with limited resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.